Address of the president-elect: the indication for various methods of treatment of occlusive cerebrovascular disease.
D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001794:Blood Pressure; D002302:Cardiac Output; D002339:Carotid Arteries / Q000503:physiopathology; D002533:Cerebral Angiography; D002560:Cerebrovascular Circulation; D002561:Cerebrovascular Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control / Q000601:surgery / Q000628:therapy*; D004176:Dipyridamole / Q000627:therapeutic use; D004569:Electroencephalography; D013700:Giant Cell Arteritis / Q000175:diagnosis; D006801:Humans; D002537:Intracranial Arteriosclerosis / Q000150:complications; D002542:Intracranial Embolism and Thrombosis / Q000209:etiology; D002546:Ischemic Attack, Transient / Q000150:complications; D008722:Methods; D009460:Neurologic Examination; D011086:Polycythemia / Q000150:complications; D011877:Radionuclide Imaging; D013442:Sulfinpyrazone / Q000627:therapeutic use
D000925:Anticoagulants; D004176:Dipyridamole; D001241:Aspirin; D013442:Sulfinpyrazone